Clinical Trial Update: A Study to Evaluate the Effect of Hepatic Impairment on the Single Dose Pharmacokinetics (PK) of Intravenous TAK-954 [Phase 1]

View source ↗

Summary

Phase 1 study evaluating how hepatic impairment affects the single-dose pharmacokinetics of intravenous TAK-954; study completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatic Impairment

Drugs mentioned

• TAK-954

Snippet

Sponsor: Takeda | Conditions: Hepatic Impairment, Healthy Volunteers | Phase 1 | Status: COMPLETED | Results posted: 2019-09-25